| Company Name | 台灣田邊製藥 |
|---|---|
| Protocol Number | TNCANA420171 |
| Title of Study | An open-label study to evaluate clinical efficacy and safety of canagliflozin in the treatment of type 2 diabetes uncontrolled with insulin therapy |
| Primary Objective | The objective of this study is to investigate the efficacy and safety of canagliflozin in patients with type 2 diabetes uncontrolled with insulin therapy. Evaluation of efficacy endpoints will be performed during and after 12 weeks of treatment, and safety evaluation will be performed throughout the entire study period. |
| Number of Sites | 1 |
| Period of Study | From：2018/03/22 to：2020/04/29 |
| Number of Patients | 30-50人 |
| IRB Approval Date | 三軍總醫院: 11/02/2017 |
| Publication Plan / Date | Unknown/未知 |
